Main Article Content
Introduction: Various dosage forms of Pueraria candollei are widely applied in folk Thai medicine for rejuvenating purpose in aged people, which correlated with its pharmacological activities reported by pre-clinical and clinical trials for menopausal symptoms. Therefore, standardized products of this plant are needed by consumers and health care personnel. Miroestrol (ME), a potent and stable phytoestrogen in P. candollei, exhibited potential to be biomarker for quality control of P. candollei samples and its products. Materials and methods: Indirect competitive enzyme-linked immunosorbant assay (ELISA) for ME determination was developed and validated by using polyclonal antibody from rabbit immunization. The correlation of ME determination between our ELISA with standard HPLC method was investigated. Finally validated ELISA was applied for P. candollei associated products. Results: Developed ELISA was comparable with published HPLC method (R2= 0.9996) in samples with various ME contents, moreover this ELISA could determine ME in samples undetectable by HPLC because of its higher sensitivity. For application, the P. candollei involved preparations contained ME of 0.766- 12.108 µg/g dry wt. Conclusion: The developed ELISA was high performance for reliable ME determination, which could be applied for P. candollei quality control in research fields and industrial productions.
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
Anusarnsoondhorn S. The remedy pamphlet of Kwao Krua tuber of Luang Anusornsuntarakromkarnpiset. Chiang Mai: Upatipongsa Press; 1931.
Chandeying V, Lamlertkittikul S. Challenges in the conduct of Thai herbal scientific study: efficacy and safety of phytoestrogen, pueraria mirifica (Kwao Keur Kao), phase I, in the alleviation of climacteric symptoms in perimenopausal women. J Med Assoc Thai 2007, 90(7):1274-1280.
Chandeying V, Sangthawan M. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study. J Med Assoc Thai 2007, 90(9):1720-1726.
Chappey O, Sandouk P, Scherrmann J-M. Monoclonal antibodies in hapten immunoassays. Pharmaceutical Research 1992, 9(11):1375-1379.
Lamlertkittikul S, Chandeying V. Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study. J Med Assoc Thai 2004, 87(1):33-40.
Virojchaiwong P, Suvithayasiri V, Itharat A. Comparison of Pueraria mirifica 25 and 50 mg for menopausal sy mptoms. Arch Gynecol Obstet 2011, 284(2):411-419.
Yusakul G, Putalun W, Udomsin O, Juengwatanatrakul T, Chaichantipyuth C. Comparative analysis of the chemical constituents of two varieties of Pueraria candollei. Fitoterapia 2011, 82(2):203-207.